Contact this trialFirst, we need to learn more about you.
PI3K/mTOR inhibitor
Samotolisib for Cancer
Recruiting1 awardPhase 2
Grand Rapids, Michigan
This trial tests how well samotolisib works in treating patients with metastatic solid tumors, NHL, or histiocytic disorders with TSC or PI3K/MTOR mutations. Samotolisib may stop cancer cell growth by blocking some enzymes needed for cell growth.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.